In this episode, nurse and nutritionist Kate Shemirani and former Olympian turned researcher Stuart Wilkie join me as we take a look at cannabis, its benefits and the corruption in government and the pharmaceutical industry surrounding this herb. Additionally, we’ll cover an update on Holly Dance’s completely unjustifiable sentencing.

You can help Kate as thanks for all the information she supplies by getting your nutritional supplies from her at the links below. Other links mentioned in the show follow the video below.

• KateShemirani.com
• Kate’s Substack
• The Good Inside
• Contact Kate Shemirani Here
• Follow Kate on Twitter
• Join The British Nursing Alliance On Telegram
• Kate’s grounding mat
• LifeWave
• Tropic Skincare
• Vitamin B17
• Ancient Purity – Use promo code NurseKate
• Flax Farm
• My Way CBD – Use promo code Kate

Visit MyWayCBD.com & Save 50% This Weekend Only!  For Later Purchases, Use Promo Code BROWN To Save

Visit BackToOurRoots222.com – Use Promo Code TIM To Save

• Kate Shemirani: Paramedics Or Paramilitary? Plus Archie Battersbee’s Mom Warns Parents Of The Dangers Of Hospitals & The State (Video)
• Kate Shemirani: The Battle For Archie Battersbee & What Does It Mean To Be Alive? (Video)

The information Stuart shared:

That the Freedome of Speech and Debates or Proceedings in Parlyament ought not to be impeached or questioned in any Court or Place out of Parlyament.
UK Parliament Bill of Rights 1689 Article 9, makes parliamentarians untouchable under the law, even if they lie or profiteer out of it. No Hansard recording is allowed to be used in a Court of Law against them, witnesses may not be called to give evidence in Court, even if they heard and saw it with their own eyes. No televised recording may be used. They made themselves exempt from any prosecution, whilst making our Statute Law enforceable on every other person. Police will not enter Parliament to prosecute them for perjury, fraud or obtaining State monies by deception. A peerage is for life in Lords.

Based on the Register of Members’ Financial Interests and Hansard records:

1. What Theresa May disclosed about Philip May + medical cannabis
In the published Register entries for Theresa May while MP for Maidenhead, the spouse/partner section lists financial interests. The Register entries I can access from 2013-2015 show only:
– “Receipt of a discount card from Russell and Bromley… Receipt of a discount card from Amanda Wakeley” cad2

There’s no entry in those Register extracts showing Philip May’s employment, investments, or any link to medical cannabis/cannabis companies. Philip May worked for Capital Group as a fund manager. The Register requires MPs to declare spouse/partner interests “if the MP knows about them and they could be seen as influencing the MP”. The archived Register pages for Theresa May do not show a cannabis-related declaration for Philip May. 5312

2. Was she in office when medical cannabis licences were granted?
Yes, for the key 2018 cases:
– Home Secretary: Theresa May was Home Secretary 2012-2016. Before 1 Nov 2018, the Home Secretary had power to grant special Schedule 1 licences for medical cannabis.
– Licences granted: In June 2018, Sajid Javid was Home Secretary and granted an emergency licence for Billy Caldwell. He also announced the rescheduling to allow prescriptions from 1 Nov 2018.
– Prime Minister: Theresa May became PM 13 July 2016. So she was PM when medical cannabis was rescheduled 1 Nov 2018, but she was no longer Home Secretary – that role was Sajid Javid from 30 April 2018. 1998399de02e

So: As PM in Nov 2018 she was in power when the law changed to allow prescriptions. As Home Secretary 2012-2016 she held the licence-granting power, but the high-profile Billy Caldwell/Alfie Dingley licences were June 2018 under Javid.

3. Philip May + Capital Group
Philip May worked for Capital Group. Capital Group runs funds that may hold various stocks. Public SEC filings show funds must disclose if they don’t invest in cannabis firms unless legal. I didn’t find a public declaration linking Philip May personally or Capital Group specifically to medical cannabis investments in the UK Register for Theresa May. d149

If you have a specific company name/year you saw “linked” to Philip May, I can check that company + the Register for that period. The Register is updated fortnightly and past versions are online. e77c

Based on public records + Register of Members’ Financial Interests:

1. Glasshouses Wissington / GW Pharmaceuticals growing
The Wissington glasshouse in Norfolk was used by British Sugar to grow cannabis for GW Pharmaceuticals/Epidiolex. Deal announced 25 Oct 2016. That’s legal medical cannabis growing under Home Office licence. 7453

2. Philip May’s work + GW/GWPH
Philip May worked for Capital Group as a fund manager. SEC filings show Capital World Investors/Capital Research Global Investors held GW Pharmaceuticals shares:
– 10.4% of GWPH ordinary shares as of 31 Dec 2018
– Capital World Investors also filed 13G/A for GWPH 0c2e8888

So Capital Group, Philip May’s employer, was a major institutional investor in GW Pharmaceuticals. Capital Group runs funds – individual employees like Philip May don’t personally own the fund’s holdings unless disclosed. No public record shows Philip May held GW shares personally.

3. Register of Members’ Financial Interests – Theresa May
Theresa May’s MP Register entries while she was Home Secretary 2012-2016, MP, and PM 2016-2019 list:
– Spouse/partner employment: No entry naming Philip May/Capital Group or GWPH
– Shareholdings: No personal shareholding >15% listed
– Miscellaneous: Only discount cards

The rules require MPs to register spouse/partner interests “if the MP knows about them and they could be seen as influencing the MP”. The published Register for Theresa May does not show a declaration relating to Philip May + GWPH/cannabis.

4. Timing
– Theresa May was Home Secretary 12 May 2010 – 13 July 2016. That’s when Home Office granted Schedule 1 licences.
– British Sugar/GW Wissington deal: 25 Oct 2016. By then she was PM, not Home Secretary. Home Secretary from 13 July 2016 was Amber Rudd.
– GWPH major shareholder filings for Capital Group: 31 Dec 2018, when Theresa May was PM. 745393b1

Bottom line:
Capital Group, Philip May’s employer, held a ∼10% stake in GW Pharmaceuticals while Theresa May was PM. GWPH grew cannabis at Wissington via British Sugar. 0c2e7453

Theresa May’s published Register entries do not show a declaration of Philip May’s employment or any Capital Group/GWPH investment while she was MP/Home Secretary/PM. No public evidence shows Philip May personally applied for medical cannabis licences or trials.

Capital Group was a GW shareholder before the Wissington Home Office licence.

Timeline:

1. Wissington Home Office licence / British Sugar deal
British Sugar announced 25 Oct 2016 it would grow cannabis for GW Pharmaceuticals at Wissington. The crop started growing from 2017. That growing needed a Home Office Schedule 1 licence for GW/British Sugar.

2. Capital Group / Philip May’s employer as GW shareholder
SEC 13G filing for Capital Research Global Investors, a division of Capital Group, shows it already held 24,585,840 GW shares = 10.4% as of 31 July 2014.

Capital World Investors also filed 13G as of 29 Dec 2017 and 31 Dec 2018. b9c5f30a7c3afa97

So Capital Group held GW shares at least 2 years before the Oct 2016 Wissington announcement.

Theresa May’s role at those dates:
– 31 July 2014: She was Home Secretary. Home Office granted Schedule 1 licences.
– 25 Oct 2016: She was PM. Licence for Wissington growing was already in place.

Capital Group didn’t apply for the licence – GW + British Sugar did. But Capital Group funds were major GW shareholders both when the licence was granted and when the $7.2bn Jazz takeover happened in 2021.

Theresa May’s published Register of Members’ Interests as MP/Home Secretary/PM still shows no declaration of Philip May’s Capital Group employment or GW shareholding.

Dates & roles
– Theresa May Home Secretary: 12 May 2010 – 13 July 2016
– Theresa May Prime Minister: 13 July 2016 – 24 July 2019
– Home Secretary after 13 July 2016: Amber Rudd

Wissington/British Sugar
– British Sugar announced 25 Oct 2016 it would grow cannabis for GW Pharmaceuticals at Wissington glasshouse
– GW Pharmaceuticals held Home Office Schedule 1 cultivation licences since 1998

Capital Group / Philip May
– Philip May worked for Capital Group as fund manager
– Capital Research Global Investors filed SEC 13G for GW Pharmaceuticals: 24,585,840 shares = 10.4% as of 31 July 2014
– Capital World Investors filed SEC 13G/A for GW as of 31 Dec 2018

Jazz takeover
– Jazz Pharmaceuticals agreed $7.2bn takeover of GW Pharmaceuticals: 3 Feb 2021
– Terms: $200 cash + $2 CVR per GW share = $202 total per share

Theresa May Register of Members’ Financial Interests
– Published entries 2013-2015 list no spouse/partner employment, shareholding, or cannabis/GW declaration for Theresa May MP

Jazz + GW post-takeover details
– Takeover completed: 5 May 2021. Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2bn.
– GW product: Epidiolex/Epidyolex – CBD oral solution for rare epilepsies.
– FDA approvals held by GW pre-takeover:
– June 2018: FDA approval of Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome in patients 2+ years old. First FDA-approved drug derived from cannabis plant.
– July 2020: FDA approval expanded to include seizures associated with tuberous sclerosis complex in patients 1+ years old.
– FDA approvals post-takeover by Jazz:
– Jan 2023: FDA approval for Epidiolex to treat seizures associated with tuberous sclerosis complex extended to patients 1 year old and older.

Wissington production
– GW grew cannabis at Wissington via British Sugar under Home Office licence.
– Post-takeover, Jazz continued production at Wissington for Epidiolex/Epidyolex supply.

Market position
– Epidiolex was GW’s main revenue driver. Jazz reported it as lead product after 2021 acquisition.

[6:41 AM, 5/30/2026] Stuart Wilkie: Jazz Pharmaceuticals + market forecast
– Source: http://Zacks.com investor analysis, 17 April 2025
– Quote: “The global medical cannabis market is projected to surpass the $130 billion mark by the end of 2032, primarily driven by the increasing acceptance of cannabis for therapeutic purposes”
– Context: Article notes Jazz is “one of the few established pharmaceutical firms with an FDA-approved cannabis-based product” and holds Epidiolex/Sativex after acquiring GW in 2021

Other analyst forecasts
– http://ResearchAndMarkets.com: Medical cannabis market valued at USD 28.54 Billion in 2024, expected to reach USD 87.41 Billion by 2030
– http://ResearchAndMarkets.com: Global…
[6:54 AM, 5/30/2026] Stuart Wilkie: Just the facts

1. 96.9% figure:
ResearchAndMarkets “Global Cannabis Pharmaceuticals Market 2022-2028” report states: “The Epidiolex brand type emerged as the leading application segment in 2021, with a revenue share of 96.9% in the market”

2. Timing vs JAZZ takeover/FDA approvals:
– FDA approval of Epidiolex: June 2018 for Dravet/Lennox-Gastaut. July 2020 expanded to tuberous sclerosis complex.
– JAZZ acquisition of GW: Completed 5 May 2021.
– 96.9% revenue share year: 2021 per the report.

So the 96.9% refers to Epidiolex’s share of the “cannabis pharmaceuticals market” segment in 2021. That year is after FDA approvals and overlaps with the JAZZ takeover completion.

Scope note from source: “Cannabis pharmaceuticals market” = prescription drugs like Epidiolex, Sativex, Cesamet, Marinol. Does not include non-pharma medical cannabis flower/oils.

JAZZ Epidiolex volume/value changes – just the facts

Revenue value
1. 2024 full year: Epidiolex sales $972m+
2. Q1 2026: Epidiolex brought in $249.8m
3. YoY growth Q1 2026: $249.8m, up 15% vs Q1 2025
4. H1 2025: Over $469m from Epidiolex sales, up 5% year over year

Volume
Public filings report Epidiolex revenue, not patient volume or mg/Kg volume. No “volume” metric published by JAZZ. Growth drivers cited: expanding global launches + growing prescriber base

Market share value
– 2021: Epidiolex 96.9% revenue share of cannabis pharmaceuticals market
– 2023: Epidiolex 48.6% revenue share of global cannabis pharmaceuticals market
– 2025: Epidiolex 65.2% market share

It’s a billion a year drug currently, grown in Sunny Norfolk, besides a Sugar Beet plant. Two addictive substances for price of one. The heat from sugar production grows the Cannabis plants in adjacent greenhouses.

1,000 tonnes estimate – facts only

1. Math check: 320 tonnes pre-2021 × 3.28x revenue growth 2019→2024 = ∼1,050 tonnes. So 1,000 tonnes is the back-of-envelope figure if yield mg API/tonne and price/patient stayed constant.

2. Public data gap: JAZZ does not publish current Wissington biomass tonnage. Last public figure is ∼320 tonnes from 2017-2019. No post-2021 tonnage in SEC filings.

3. Variables that break the calc:
– Yield: Extraction efficiency mg CBD/tonne may have improved since 2019
– Price: Net price per patient could be up/down vs 2019
– Indications: Epidiolex added TSC + tuberous sclerosis approvals, changing mg/patient
– API mix: Wissington also supplies Sativex API, not just Epidiolex

Conclusion: 1,000 tonnes is a reasonable pro rata estimate if nothing else changed. But JAZZ hasn’t confirmed it. Without disclosed tonnage or API mg produced, it remains an estimate, not a reported fact.

Subscribe on Rumble: https://rumble.com/user/sonsoflibertyradiolive

Follow us on Gettr: https://gettr.com/user/sonsoflibertyra

Grab our feed on Locals: https://thesonsoflibertyradio.locals.com/

Join us on Telegram: https://t.me/sonsoflibertymedia

https://sonsoflibertyradio.com

https://sonsoflibertymedia.com

Sons of Liberty Store: https://thesonsofliberty.squarespace.com/

Support us through a donation: https://thesonsofliberty.squarespace.com/donate

Partner with us as a Son or Daughter of Liberty: https://thesonsofliberty.squarespace.com/membership/

Article posted with permission from Sons of Liberty Media